The complexity of the dopaminergic synapses and their modulation by antipsychotics

Pharmacopsychiatry

Volumn 39, Issue SUPPL. 1, 2006, Pages

  Leuner, K ^a   Muller W E ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ARTICLE; BINDING AFFINITY; BRAIN CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; HUMAN; LIMBIC SYSTEM; MODULATION; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; TUBEROHYPOPHYSEAL TRACT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; HUMANS; NERVE NET; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SYNAPSES; TREATMENT OUTCOME;

EID: 33644817074     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931484     Document Type: Article

References (34)

1. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 2005; 20: 15-27
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 8104-8109
3. Bonci A, Hopf FW. The dopamine D2 receptor: New surprises from an old friend. Neuron 2005; 47: 335-338
4. Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 1997; 18: 186-188
5. Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current therapeutics. Curr.Med.Chem 2002; 9: 521-548
6. Chang WH, Jaw SS, Tsay L. Chronic Haloperidol Treatment with Low-Doses May Enhance the Increase of Homovanillic-Acid in Rat-Brain. European Journal of Pharmacology 1989; 162: 151-156
7. De Camilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979; 278: 252-254
8. Dresel S, Mager T, Rossmuller B, Meisenzahl E, Hahn K, Moller HJ, Tatsch K. In vivo effects of olanzapine on striatal dopamine D-2/D-3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. European Journal of Nuclear Medicine 1999; 26: 862-868
9. Farde L, Nordstrom AL, Karlsson P, Halldin C, Sedvall G. Positron Emission Tomography Studies on Dopamine-Receptors in Schizophrenia. Clinical Neuropharmacology 1995; 18: S121-129
10. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544
11. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004; 174: 3-16
12. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends in Neurosciences 1997; 20: 31-37
13. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia - A postmortem study. Archives of General Psychiatry 1997; 54: 225-232
14. Huff RM. Signaling pathways modulated by dopamine receptors. 1997: 167-192
15. Joyce JN, Milian MJ. Dopamine D-3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005; 10: 917-925
16. Kapur S, Mamo D. Haifa century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-1090
17. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol.Psychiatry 2005; 10: 79-104
18. Moller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics - Two different pharmacological mechanisms? European Archives of Psychiatry and Clinical Neuroscience 2005; 255: 190-201
19. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. Journal of Receptors and Signal Transduction 2004; 24: 165-205
20. Nordstrom AL, Farde L, Eriksson L, Halldin C. No Elevated D-2 Dopamine-Receptors in Neuroleptic-Naive Schizophrenic-Patients Revealed by Positron Emission Tomography and [C-11] N-Methylspiperone. Psychiatry Research-Neuroimaging 1995; 61: 67-83
21. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C. Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol.Psychiatry 1993; 33: 227-235
22. Okubo Y, Suhara T, Sudo Y, Toru M. Possible role of dopamine D1 receptors in schizophrenia. Molecular Psychiatry 1997; 2: 291-292
23. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine Dl receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-636
24. Seeman P. Dopamine Receptor Sequences - Therapeutic Levels of Neuroleptics Occupy D2-Receptors, Clozapine Occupies D4. Neuropsychopharmacology 1992; 7: 261-284
25. Seeman P and Kapur S. Olanzapine Binding to Dopamine Receptors in Vitro and in Vivo. In Tran, PV et al., editors. Olanzapine (Zyprexa* ): A novel antipsychotic. Philadelphia: Lippincott Williams & Wilkings; 2000. p. 3-24
26. Seeman P, Kapur S. Schizophrenia: More dopamine, more D-2 receptors. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 7673-7675
27. Seeman P, Lee T, Chauwong M, Wong K. Antipsychotic Drug Doses and Neuroleptic-Dopamine Receptors. Nature 1976; 261: 717-719
28. Seeman P, Weinshenker D, Quirion R, Srivastava IAK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El Ghundi M, O'Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T. Dopamine supersensitivity correlates with D2(High) states, implying many paths to psychosis. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 3513-3518
29. Stevens JR. Anatomy of Schizophrenia. Archives of General Psychiatry 1973; 29: 177-189
30. Strange PG. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological Reviews 2001; 53: 119-133
31. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [I-123]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002; 162: 42-49
32. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am.J.Psychiatry 1999; 156: 419-425
33. Wadenberg MLG, Jones C, Kapur S, Soliman A, Vaccarino F, Wilson A. Quantitative relationship between in vivo dopamine D2 receptor occupancy and catalepsy in rats. International Journal of Psychology 2000; 35: 421-421
34. Wong DF, Young D, Wilson PD, Meltzer CC, Gjedde A. Quantification of neuroreceptors in the living human brain. D-2-like dopamine receptors: Theory, validation, and changes during normal aging. Journal of Cerebral Blood Flow and Metabolism 1997; 17: 316-330